Citi analyst Yigal Nochomovitz lowered the firm’s price target on Caribou Biosciences to $30 from $37 and keeps a Buy rating on the shares. The analyst updated the company’s model post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRBU:
- Caribou Biosciences to Participate in Upcoming Investor Conferences
- Caribou Biosciences reports Q2 EPS (48c), consensus (49c)
- Caribou Biosciences price target lowered to $23 from $25 at H.C. Wainwright
- Caribou Biosciences’ data in LBCL looks ‘solid,’ says Truist
- Caribou Biosciences 19.23M share Spot Secondary priced at $6.50
